Morphea in Childhood: An Update.

Area of Science:

• Dermatology
• Pediatric Autoimmune Diseases

Background:

• Morphea, also known as localized juvenile scleroderma, is an inflammatory and fibrosing skin disorder.
• It predominantly affects girls, typically appearing between 5 and 7 years of age.
• A classification system identifies five types: circumscribed, linear, generalized, pansclerotic, and mixed.

Purpose of the Study:

• To provide an overview of childhood morphea, including its classification, clinical presentation, and management.
• To highlight the extracutaneous manifestations and treatment options for pediatric morphea.
• To discuss prognostic factors and potential long-term outcomes of the disease.

Main Methods:

• Review of existing literature and classification systems for morphea.
• Summary of current therapeutic modalities, including phototherapy and various pharmacological agents.
• Discussion of monitoring tools and prognostic indicators based on available studies.

Main Results:

• Morphea presents in various forms, with approximately 40% of patients experiencing extracutaneous manifestations.
• Treatment options are diverse, encompassing phototherapy, topical and oral medications like calcitriol, tacrolimus, methotrexate, corticosteroids, mycophenolate mofetil, bosentan, and imiquimod.
• Prognostic data suggest a chronic or intermittent-recurrent disease course, often leading to sequelae.

Conclusions:

• Childhood morphea is a complex condition requiring a multi-faceted treatment approach.
• Effective management involves a combination of therapies and monitoring tools to address both cutaneous and extracutaneous involvement.
• The chronic nature of morphea underscores the importance of long-term follow-up to manage potential sequelae.